Pharmacokinetics characterization of liposomal amphotericin B: Investigation of clearance process and drug interaction potential

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 9, 2009, Pages 461-470

  Matsui, Satomi ^a   Imai, Satoki ^a   Yabuki, Masashi ^a   Komuro, Setsuko ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

AmBisome ; Antifungal drugs; CAS 1397 89 3; Liposomal amphotericin B, metabolism, pharmacokinetics

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CAS 1397 89 3; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2B1; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNION FLUID; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TISSUE LEVEL; FEMALE; FETUS; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LIVER CLEARANCE; LIVER FAILURE; LIVER MICROSOME; LIVER WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; MILK; NONHUMAN; PLACENTA; PLACENTAL TRANSFER; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70449643443     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296426     Document Type: Article

References (28)

1. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis . 2005;41(4):521-526
2. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37(3):415-425
3. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301.
4. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol. 1998;36(Suppl 1):119-128 (Pubitemid 128692084)
5. Ellis D. Amphotericin B: spectrumand resistance. J Antimicrob Chemother . 2002;49(Suppl 1):7-10.
6. Abu-Salah KM. Amphotericin B: an update. Br J Biomed Sci. 1996;53(2):122-133
7. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343-500.
8. Maniwa T, Yamamoto Y. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)]. Nippon Yakurigaku Zasshi. 2007;129(2):129-134 (Pubitemid 351325804)
9. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol. 1998;38(7):583-592 (Pubitemid 28354895)
10. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002;49(Suppl 1):21-30. (Pubitemid 34162653)
11. Alpini G, Phillips JO, Vroman B, LaRusso NF. Recent advances in the isolation of liver cells. Hepatology. 1994; 20(2):494-514. (Pubitemid 24233378)
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-275
13. Omura T, Sato R. The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature. J Biol Chem. 1964;239:2370-2378
14. Vermilion JL, Coon MJ. Highly purified detergent-solubilized NADPH-cytochrome P-450 reductase from phenobarbital-induced rat liver microsomes. Biochem Biophys Res Commun. 1974;60(4):1315-1322
15. Jayyosi Z, Knoble D, Muc M, Erick J, Thomas PE, Kelley M. Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. off. J Pharmacol Exp Ther. 1995;273(3):1156-1161
16. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002;46(3):834-840 (Pubitemid 34157671)
17. Juliano RL. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv Drug Deliv Rev. 1988;2:31-54.
18. Townsend RW, Zutshi A, Bekersky I. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos. 2001; 29(5):681-685
19. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991;35(6):1208-1213
20. Dean JL, Wolf JE, Ranzini AC, Laughlin MA. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis. 1994;18(3):364-368 (Pubitemid 24086306)
21. Davies B, Morris T. Physiological parameters in laboratory animals and humans. PharmRes. 1993;10(7):1093-1095 (Pubitemid 23211439)
22. Gregoriadis G. Overview of liposomes. J Antimicrob Chemother. 1991;28(Suppl B):39-48.
23. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res. 2000;17(12): 1494-1502. (Pubitemid 32217558)
24. Kume Y, Maeda F, Harashima H, Kiwada H. Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system. J PharmPharmacol. 1991;43(3):162-166
25. Harashima H. Pharmacokinetic studies on the drug delivery system using liposomes. Yakubutsu Dotai. 1995;10(4): 566-575
26. Chow DD, Essien HE, Padki MM, Hwang KJ. Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther. 1989;248(2):506-513
27. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828-833 (Pubitemid 34157670)
28. Inselmann G, Volkmann A, Heidemann HT. Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cytochrome P-450 in rats. Antimicrob Agents Chemother . 2000;44(1):131-133 (Pubitemid 30010682)